{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T05:25:04Z","timestamp":1774329904371,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Prostaglandins & Other Lipid Mediators"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.prostaglandins.2024.106919","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T13:35:25Z","timestamp":1731504925000},"page":"106919","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The effect of medroxyprogesterone acetate on apolipoproteins and lipoprotein(a) concentrations in postmenopausal women: A meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"176","author":[{"given":"Qiujin","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kousalya","family":"Prabahar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.prostaglandins.2024.106919_bib1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0009-2797(78)90105-9","article-title":"Importance of apolipoproteins in lipid metabolism","volume":"20","author":"Cham","year":"1978","journal-title":"Chem. -Biol. Interact."},{"issue":"12","key":"10.1016\/j.prostaglandins.2024.106919_bib2","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0022-2275(20)34443-6","article-title":"Plasma lipoproteins: apolipoprotein structure and function","volume":"25","author":"Mahley","year":"1984","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.prostaglandins.2024.106919_bib3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1023\/A:1007111830472","article-title":"High density lipoprotein, apolipoprotein A-1, and coronary artery disease","volume":"209","author":"Srivastava","year":"2000","journal-title":"Mol. Cell. Biochem."},{"issue":"1","key":"10.1016\/j.prostaglandins.2024.106919_bib4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2217\/17584299.4.1.113","article-title":"Activation of lecithin: cholesterol acyltransferase by HDL ApoA-I central helices","volume":"4","author":"Sorci-Thomas","year":"2009","journal-title":"Clin. Lipidol."},{"issue":"11","key":"10.1016\/j.prostaglandins.2024.106919_bib5","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/S0022-2275(20)38425-X","article-title":"Plasma very low density lipoproteins contain a single molecule of apolipoprotein B","volume":"29","author":"Elovson","year":"1988","journal-title":"J. Lipid Res."},{"issue":"9298","key":"10.1016\/j.prostaglandins.2024.106919_bib6","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0140-6736(01)07098-2","article-title":"High apolipoprotein B, low apolipoprotein AI, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study","volume":"358","author":"Walldius","year":"2001","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.prostaglandins.2024.106919_bib7","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.3390\/biomedicines9111579","article-title":"Lipoproteins and cardiovascular disease: an update on the clinical significance of atherogenic small, dense LDL and new therapeutical options","volume":"9","author":"Rizvi","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.prostaglandins.2024.106919_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12863-021-00968-1","article-title":"Association between apolipoprotein gene polymorphisms and hyperlipidemia: a meta-analysis","volume":"22","author":"Zhao","year":"2021","journal-title":"Bmc Genom. Data"},{"issue":"4","key":"10.1016\/j.prostaglandins.2024.106919_bib9","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.metabol.2012.07.024","article-title":"Lipoprotein (a) metabolism: potential sites for therapeutic targets","volume":"62","author":"Hoover-Plow","year":"2013","journal-title":"Metabolism"},{"issue":"23","key":"10.1016\/j.prostaglandins.2024.106919_bib10","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein (a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur. Heart J."},{"issue":"5","key":"10.1016\/j.prostaglandins.2024.106919_bib11","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/07853890.2020.1775287","article-title":"Lipoprotein (a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options","volume":"52","author":"Rehberger Likozar","year":"2020","journal-title":"Ann. Med."},{"issue":"2","key":"10.1016\/j.prostaglandins.2024.106919_bib12","doi-asserted-by":"crossref","first-page":"458","DOI":"10.5114\/aoms\/157308","article-title":"Menopause and women\u2019s cardiovascular health: is it really an obvious relationship?","volume":"19","author":"Ryczkowska","year":"2023","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.prostaglandins.2024.106919_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2021\/5523516","article-title":"Protective effects of estrogen on cardiovascular disease mediated by oxidative stress","volume":"2021","author":"Xiang","year":"2021","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.prostaglandins.2024.106919_bib14","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.maturitas.2022.08.001","article-title":"Dyslipidemia in midlife women: approach and considerations during the menopausal transition","volume":"166","author":"Torosyan","year":"2022","journal-title":"Maturitas"},{"issue":"10","key":"10.1016\/j.prostaglandins.2024.106919_bib15","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1161\/01.CIR.97.10.979","article-title":"Effect of postmenopausal hormone therapy on lipoprotein (a) concentration","volume":"97","author":"Espeland","year":"1998","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.prostaglandins.2024.106919_bib16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/MNH.0b013e3283431921","article-title":"Estrogen, hormonal replacement therapy and cardiovascular disease","volume":"20","author":"Yang","year":"2011","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"issue":"3","key":"10.1016\/j.prostaglandins.2024.106919_bib17","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/GME.0b013e31829a64f9","article-title":"Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: Findings from the WHI observational study","volume":"21","author":"Shufelt","year":"2014","journal-title":"Menopause (N. Y., NY)"},{"key":"10.1016\/j.prostaglandins.2024.106919_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104693","article-title":"Postmenopausal hormone therapy and Alzheimer's disease, dementia, and Parkinson's disease: a systematic review and time-response meta-analysis","volume":"155","author":"Wu","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.prostaglandins.2024.106919_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.exger.2022.112055","article-title":"The effect of 17\u03b2-estradiol plus norethisterone acetate treatment on lipoprotein (a), atherogenic and anti-atherogenic apolipoproteins levels in postmenopausal women: a meta-analysis of randomized controlled trials","volume":"172","author":"Tang","year":"2023","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.prostaglandins.2024.106919_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.steroids.2022.109061","article-title":"The effect of transdermal 17\u03b2-estradiol combined with norethisterone acetate treatment on the lipid profile in postmenopausal women: a meta-analysis and systematic review of randomized controlled trials","volume":"185","author":"Tao","year":"2022","journal-title":"Steroids"},{"key":"10.1016\/j.prostaglandins.2024.106919_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2023.09.002","article-title":"Effects of Transdermal 17\u03b2-Estradiol+ Norethisterone acetate on cardiovascular disease risk factors in postmenopausal women: a meta-analysis of data from randomized, controlled trials","author":"Lan","year":"2023","journal-title":"Clin. Ther."},{"key":"10.1016\/j.prostaglandins.2024.106919_bib22","doi-asserted-by":"crossref","unstructured":"Li, C., M. Wei, L. Mo, P. Velu, K. Prabahar, M.-A. G\u0103man, et al., The effect of tibolone treatment on apolipoproteins and lipoprotein (a) concentrations in postmenopausal women: A meta-analysis of randomized controlled trials. European Journal of Obstetrics & Gynecology and Reproductive Biology, 2023.","DOI":"10.1016\/j.ejogrb.2023.10.020"},{"issue":"3","key":"10.1016\/j.prostaglandins.2024.106919_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000402.pub2","article-title":"Hormone therapy in postmenopausal women and risk of endometrial hyperplasia","author":"Furness","year":"2004","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.prostaglandins.2024.106919_bib24","article-title":"The impact of medroxyprogesterone acetate on lipid profiles in Women: a time and dose-response meta-analysis of randomized controlled trials","author":"Feng","year":"2023","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"9","key":"10.1016\/j.prostaglandins.2024.106919_bib25","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/ptj\/89.9.873","article-title":"and P. Group, Reprint\u2014preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"89","author":"Moher","year":"2009","journal-title":"Phys. Ther."},{"key":"10.1016\/j.prostaglandins.2024.106919_bib26","unstructured":"Higgins, J., GSe. Cochrane handbook for systematic reviews of interventions version, 2011. 5(0)."},{"issue":"1","key":"10.1016\/j.prostaglandins.2024.106919_bib27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med. Res. Methodol."},{"issue":"7109","key":"10.1016\/j.prostaglandins.2024.106919_bib28","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"and C. Minder, Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Bmj"},{"issue":"3","key":"10.1016\/j.prostaglandins.2024.106919_bib29","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/GME.0000000000000992","article-title":"Initial investigation into the optimal dose ratio of conjugated estrogens and bazedoxifene: a double-blind, randomized, placebo-controlled phase 2 dose-finding study","volume":"25","author":"Pickar","year":"2018","journal-title":"Menopause"},{"issue":"5","key":"10.1016\/j.prostaglandins.2024.106919_bib30","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3109\/13697131003624656","article-title":"Hot flushes and biochemical markers for cardiovascular disease: a randomized trial on hormone therapy","volume":"13","author":"Tuomikoski","year":"2010","journal-title":"Climacteric"},{"issue":"6","key":"10.1016\/j.prostaglandins.2024.106919_bib31","article-title":"Can biomarkers identify women at increased stroke risk? The Women's Health Initiative hormone trials","volume":"2","author":"Kooperbergl","year":"2007","journal-title":"PLoS Clin. Trials"},{"issue":"5","key":"10.1016\/j.prostaglandins.2024.106919_bib32","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00404-006-0187-2","article-title":"The effect of hormone replacement therapy on the levels of serum lipids, apolipoprotein AI, apolipoprotein B and lipoprotein (a) in Turkish postmenopausal women","volume":"274","author":"Bayrak","year":"2006","journal-title":"Arch. Gynecol. Obstet."},{"issue":"5","key":"10.1016\/j.prostaglandins.2024.106919_bib33","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/09513590410001715207","article-title":"Effect of hormone replacement therapy, tibolone and raloxifene on serum lipids, apolipoprotein A1, apolipoprotein B and lipoprotein(a) in Greek postmenopausal women","volume":"18","author":"Christodoulakos","year":"2004","journal-title":"Gynecol. Endocrinol."},{"issue":"10","key":"10.1016\/j.prostaglandins.2024.106919_bib34","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0026-0495(03)00276-2","article-title":"Effects of estrogen and medroxyprogesterone acetate on subpopulations of triglyceride-rich lipoproteins and high-density lipoproteins","volume":"52","author":"Lamon-Fava","year":"2003","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.prostaglandins.2024.106919_bib35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0015-0282(01)01829-5","article-title":"Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism","volume":"76","author":"Lobo","year":"2001","journal-title":"Fertil. Steril."},{"issue":"18","key":"10.1016\/j.prostaglandins.2024.106919_bib36","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/jama.279.18.1445","article-title":"Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women","volume":"279","author":"Walsh","year":"1998","journal-title":"Jama"},{"issue":"10","key":"10.1016\/j.prostaglandins.2024.106919_bib37","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1161\/01.CIR.97.10.979","article-title":"Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal Estrogen\/Progestin Interventions","volume":"97","author":"Espeland","year":"1998","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.prostaglandins.2024.106919_bib38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0378-5122(96)01044-4","article-title":"Effects of continuous medroxyprogesterone acetate on lipoprotein metabolism in postmenopausal women receiving estrogen","volume":"25","author":"Wakatsuki","year":"1996","journal-title":"Maturitas"},{"issue":"15","key":"10.1016\/j.prostaglandins.2024.106919_bib39","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1001\/archinte.1996.00440140123012","article-title":"Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women: influence of various progestogens and duration of therapy","volume":"156","author":"Kim","year":"1996","journal-title":"Arch. Intern. Med."},{"issue":"22","key":"10.1016\/j.prostaglandins.2024.106919_bib40","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein (a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"Jama"},{"issue":"18","key":"10.1016\/j.prostaglandins.2024.106919_bib41","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1093\/eurjpc\/zwaa063","article-title":"Lipoprotein (a) and cardiovascular disease: prediction, attributable risk fraction, and estimating benefits from novel interventions","volume":"28","author":"Welsh","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"3","key":"10.1016\/j.prostaglandins.2024.106919_bib42","first-page":"381","article-title":"Lipoprotein (a) is associated with cardiovascular events in low risk males: results from a health checkup cohort with long-term follow-up","volume":"38","author":"Huang","year":"2022","journal-title":"Acta Cardiol. Sin."},{"key":"10.1016\/j.prostaglandins.2024.106919_bib43","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.maturitas.2019.09.005","article-title":"Changes in lipoprotein subfractions following menopause in the Longitudinal Study of Adult Health (ELSA-Brasil)","volume":"130","author":"Fonseca","year":"2019","journal-title":"Maturitas"},{"issue":"5","key":"10.1016\/j.prostaglandins.2024.106919_bib44","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S1567-5688(09)71817-3","article-title":"Cardiovascular events in patients with increased lipoprotein (a)\u2013retrospective data analysis in an outpatient department of lipid disorders","volume":"10","author":"Tselmin","year":"2009","journal-title":"Atheroscler. Suppl."},{"issue":"10","key":"10.1016\/j.prostaglandins.2024.106919_bib45","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3390\/metabo11100690","article-title":"Apolipoprotein B and cardiovascular disease: biomarker and potential therapeutic target","volume":"11","author":"Behbodikhah","year":"2021","journal-title":"Metabolites"},{"issue":"7","key":"10.1016\/j.prostaglandins.2024.106919_bib46","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s11883-022-01025-7","article-title":"ApoA-I infusion therapies following acute coronary syndrome: past, present, and future","volume":"24","author":"Kalayci","year":"2022","journal-title":"Curr. Atheroscler. Rep."},{"issue":"23","key":"10.1016\/j.prostaglandins.2024.106919_bib47","doi-asserted-by":"crossref","first-page":"16178","DOI":"10.1074\/jbc.M709597200","article-title":"ATP-binding cassette A1-mediated lipidation of apolipoprotein AI occurs at the plasma membrane and not in the endocytic compartments","volume":"283","author":"Denis","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.prostaglandins.2024.106919_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003853","article-title":"Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB\/apoA-1 ratio\u2014Experience from the Swedish AMORIS cohort: a cohort study","volume":"18","author":"Walldius","year":"2021","journal-title":"PLoS Med."},{"issue":"4","key":"10.1016\/j.prostaglandins.2024.106919_bib49","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1172\/JCI8623","article-title":"The role of the LDL receptor in apolipoprotein B secretion","volume":"105","author":"Twisk","year":"2000","journal-title":"J. Clin. Investig."},{"issue":"3","key":"10.1016\/j.prostaglandins.2024.106919_bib50","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/01.ATV.16.3.431","article-title":"Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein A-I and lowers hepatic lipase activity without lowering the fractional catabolic rate","volume":"16","author":"Brinton","year":"1996","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"2","key":"10.1016\/j.prostaglandins.2024.106919_bib51","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1161\/01.ATV.0000199248.53590.e1","article-title":"Role of the estrogen and progestin in hormonal replacement therapy on apolipoprotein A-I kinetics in postmenopausal women","volume":"26","author":"Lamon-Fava","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"7","key":"10.1016\/j.prostaglandins.2024.106919_bib52","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0026-0495(96)90165-1","article-title":"Estrogen increases low-density lipoprotein receptor-independent catabolism of apolipoprotein B in hyperlipidemic rabbits.","volume":"45","author":"Colvin Jr.","year":"1996","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.prostaglandins.2024.106919_bib53","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s12944-017-0612-5","article-title":"The effects of progesterones on blood lipids in hormone replacement therapy","volume":"16","author":"Jiang","year":"2017","journal-title":"Lipids Health Dis."},{"issue":"13","key":"10.1016\/j.prostaglandins.2024.106919_bib54","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2013.278040","article-title":"Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials","volume":"310","author":"Manson","year":"2013","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.prostaglandins.2024.106919_bib55","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0378-5122(98)00104-2","article-title":"The heart and estrogen\/progestin replacement study (HERS)","volume":"31","author":"Speroff","year":"1998","journal-title":"Maturitas"},{"key":"10.1016\/j.prostaglandins.2024.106919_bib56","article-title":"The impact of medroxyprogesterone acetate on lipid profiles in Women: a time and dose-response meta-analysis of randomized controlled trials","author":"Feng","year":"2023","journal-title":"Diabetes Res. Clin. Pr."}],"container-title":["Prostaglandins & Other Lipid Mediators"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882324001138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882324001138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T21:56:34Z","timestamp":1737323794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098882324001138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":56,"alternative-id":["S1098882324001138"],"URL":"https:\/\/doi.org\/10.1016\/j.prostaglandins.2024.106919","relation":{},"ISSN":["1098-8823"],"issn-type":[{"value":"1098-8823","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of medroxyprogesterone acetate on apolipoproteins and lipoprotein(a) concentrations in postmenopausal women: A meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Prostaglandins & Other Lipid Mediators","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prostaglandins.2024.106919","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106919"}}